Complementary platforms that act alone or in combination with other treatments to treat cancer and chronic diseases.
First-in-Class small molecules with lead candidate RRx-001
RRx-001 in Small Cell Lung Cancer | Phase 3
3L+ SCLC “REPLATINUM” Phase 3 study enrolling in US and China
Sensitizing tumors to respond to platinum-based chemotherapy.
eLoop Administration Device | Phase 3
Proprietary device designed for optimized IV delivery of RRx-001.
RRx-001 Pilot Studies | Preclinical
Programs include Liver Cancer and Leukemia.
RRx-001 in radiation protection | Phase 2
As a pretreatment in 1L Head & Neck Cancer Prevention of radiation induced oral mucositis.
RRx-001 Inflammasome Inhibition | Preclinical
Chronic diseases linked to uncontrolled or dysfunctional inflammation regulated by the inflammasome.
Cancer Targeting Viruses with lead candidate AdAPT-001
AdAPT-001 “TGFβ trap” | Phase 1
“BETA PRIME” Phase 1 study of the AdAPT cancer-targeting virus technology with TGFβ neutralizing enhancement for immune activation against cancer.
AdAPT-PSV “Personalized” | Phase 1
Patient specific cancer mutations (neoantigens) are added to our cancer targeting virus.
AdAPT-002 (undisclosed) | Preclinical
The next AdAPT Platform cancer targeting virus.
AdAPT Nanoparticle Encapsulation | Preclinical
Optimization of AdAPT Platform treatments for improved delivery and performance.
Our currently active clinical trials.
Study: REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Carcinoma
Conditions: Small Cell Lung Cancer
Interventions: Drug: RRx-001; Drug: Cisplatin/carboplatin
ClinicalTrials.gov Identifier: NCT03699956
Study: BETA PRIME: A Phase I, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors. 3 + 3 dose escalation safety run-in (Part 1) followed by a dose expansion single-agent (Part 2) and completing with AdAPT-001 combined with an immune checkpoint inhibitor (Part 3).
Conditions: Solid Tumors, palpable / easily accessible for needle injection
Interventions: Drug: AdAPT-001
ClinicalTrials.gov Identifier: NCT04673942
Study: PIRATE: RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
Conditions: Brain Tumor, Recurrent; Brain Tumor, Pediatric; Central Nervous System Neoplasms; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: RRx-001; Drug: Temozolomide; Drug: Irinotecan
ClinicalTrials.gov Identifier: NCT04525014